Company news

Chimeric Therapeutics Limited news in 2023

Chimeric Therapeutics Limited's news releases, calls and decks from 2023, newest first.

View company

Positive in vitro data for CHM 1301 CAR NK cells

November 22, 2023

1st patient dosed in Phase 1b recurrent glioblastoma trial

November 1, 2023

FDA clearance of IND for CHM 2101

October 30, 2023

Entitlement Offer to raise approximately $10 million

October 24, 2023

New data for Phase 1A CLTX CAR T brain cancer clinical trial

October 22, 2023

Agreement with MD Anderson for Phase 1B CHM 0201 AML study

September 12, 2023

Dosing completion in Phase 1A brain cancer clinical trial

August 28, 2023

Chimeric to receive A$4.4 million introduction fee

August 16, 2023

Positive data - CHM 0301 next-gen armoured NK cell platform

August 14, 2023

CHM secures up to A$12.6m through SPP and placements

June 23, 2023

Share purchase plan completed

June 23, 2023

Launch of new Phase 1B Glioblastoma clinical trial

June 4, 2023

SPP offer documents issued to shareholders

May 22, 2023

Board & management commit to $1M placement and proposed spp

May 15, 2023

New CLTX CAR technology patent protection in India & Israel

April 28, 2023

Phase 1B brain cancer clinical trial approved for initiation

April 25, 2023

CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

April 3, 2023

Positive pre-IND meeting with FDA for Phase 1 CAR T study

March 20, 2023

Fourth dose cohort initiated in CHM 1101 Phase 1 trial

March 2, 2023

Appendix 4D and Half Year Report

February 28, 2023

Chimeric receives $3.06M R&D tax incentive

February 14, 2023

Follow up period completed for 3rd cohort in CHM 1101 trial

January 22, 2023

Decks in 2023